CAR‑T cell therapy has revolutionized the treatment of hematological and solid tumors, sparking global interest in cancer R&D. Alfa Cytology, a global leader in bioreagents and a preclinical research service provider, offers comprehensive solutions from early target discovery to preclinical development. Our proprietary alfaCAR‑T™ platform is engineered for enhanced durability and persistent efficacy, delivering robust, long‑lasting anti‑tumor responses.
Chimeric antigen receptors (CARs) are engineered constructs designed to augment natural T cell receptors (TCRs). They comprise four principal components:
Fig.1 The introduction of CAR-T cells. (Yang, Y. H., et al., 2022)
Currently, five generations of CAR‐T have been developed with different characteristics.
| Type | Brief Description |
| First Generation CAR-T | Contain only the CD3ζ signaling domain, resulting in limited T cell activation, expansion, and persistence. |
| Second Generation CAR-T | Incorporate a costimulatory domain (e.g., CD28, 4-1BB, or ICOS) alongside CD3ζ to enhance T cell activation, proliferation, and persistence. |
| Third Generation CAR-T | Combine multiple costimulatory domains (e.g., CD28/ICOS and 4-1BB/CD27/OX-40) with CD3ζ, though they do not consistently demonstrate superior activation compared to the second generation. |
| Fourth Generation CAR-T | Add an NFAT-driven inducible cytokine module (e.g., IL-12) to the second-generation design, enhancing anti-tumor efficacy and modifying the tumor microenvironment. |
| Fifth Generation CAR-T | Integrate an IL-2Rβ domain and transcription factors (STAT3/STAT5) between the costimulatory and CD3ζ domains to further boost T cell proliferation, persistence, and anti-tumor activity. |
alfaCAR-T™ is an advanced CAR-T development platform focused on delivering potent and sustained cancer immunotherapies. By integrating state-of-the-art engineering, optimized antigen targeting, and proprietary enhancements for immune persistence, alfaCAR-T™ addresses many of the limitations commonly associated with traditional CAR-T approaches.
| Key Parameter | Conventional CAR-T | alfaCAR-T™ |
| Durability of Response | May wane over time, often requiring additional interventions | Engineered for extended anti-tumor activity, reducing relapse rates |
| Immune Memory Formation | Limited memory T cell generation, lower long-term surveillance | Enhanced T cell memory, providing sustained immunological vigilance |
| Tumor Microenvironment | Susceptible to immunosuppressive factors in solid tumors | Improved resilience in harsh tumor environments, boosting efficacy |
| Antigen Targeting | Standard scFv-based constructs with variable specificity | Optimized antigen-binding domains for high specificity and fewer off-target effects |
alfaCAR-T™ platform is committed to expediting the discovery and optimization of CAR-T therapies, offering an integrated solution for preclinical immunotherapy research.
Antigen Discovery
Comprehensive Quality Check
Tailored Approach to CAR‑T Innovation
Every step is customized for optimal therapeutic outcomes.
Emphasis on Durability & Memory
Designed to enhance T-cell durability and reduce relapse.
Unparalleled Technical Expertise
Expert teams deliver cutting-edge solutions and research.
Partner with us to accelerate your CAR-T cell therapy development. Alfa Cytology provides tailored solutions that cover every stage of CAR-T engineering—from precise construct design and rigorous characterization to optimized production and quality assurance. Contact us today to discuss how our innovative CAR-T development services can help you overcome therapeutic hurdles.
Reference
For research use only.
Alfa Cytology, a pioneer in alfaCAR-TTM therapy, provides integrated preclinical solutions to accelerate next-generation cancer immunotherapy development. Our technology platform combines advanced alfaCAR-TTM design, precision engineering, and multi-dimensional characterization to overcome key challenges and expedite therapy translation.
Copyright © 2025 Alfa Cytology. All rights reserved.
